MARKET INTRODUCTION
Monoamine oxidase inhibitors (MAOI) are drugs which help to inhibit the activity of monoamine oxidase enzymes A and B. These are used in the treatment of anxiety, depression, Parkinson's disease, dysthymia, and other type of disorders. These are the first type of manufactured antidepressant drugs. These drugs have the availability to remove dopamine, neurotransmitters serotonin, and norepinephrine from the brain. These drugs require certain diet restrictions as they effect blood pressure of patients when taken with other prescribed patients.
MARKET DYNAMICS
Factors driving the growth of the monoamine oxidase inhibitor market are the presence of large population base suffering from anxiety, and growing awareness among the population regarding mental health. However, patent expiry and, the side-effects associated with MAOI's is likely to hamper the growth of this market.
MARKET SCOPE
The "Monoamine Oxidase Inhibitor Market Analysis to 2028" is a specialized and in-depth study of the healthcare industry with a special focus on the global market trend analysis. The report aims to provide an overview of monoamine oxidase inhibitor market with detailed market segmentation by type, and application. The monoamine oxidase inhibitor market is expected to witness high growth during the forecast period. The report provides key statistics on the market status of the leading players in monoamine oxidase inhibitor market and offers key trends and opportunities in the market.
MARKET SEGMENTATION
The monoamine oxidase inhibitor market is segmented on the basis of type, and application. On the basis of type, the market is categorized as Nonselective MAO-A MAO-B inhibitors, and selective MAO-A/ MAO-B inhibitors. On the basis of application the market is categorized as atypical depression treatment, Parkinson's disease treatment, and other therapies.
REGIONAL FRAMEWORK
The report provides a detailed overview of the industry including both qualitative and quantitative information. It provides overview and forecast of the monoamine oxidase inhibitor market based on various segments. It also provides market size and forecast estimates from year 2020 to 2028 with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South & Central America. The monoamine oxidase inhibitor market by each region is later sub-segmented by respective countries and segments. The report covers analysis and forecast of 18 countries globally along with current trend and opportunities prevailing in the region.
The report analyzes factors affecting monoamine oxidase inhibitor market from both demand and supply side and further evaluates market dynamics affecting the market during forecast period i.e., drivers, restraints, opportunities, and future trend. The report also provides exhaustive PEST analysis for all five regions namely; North America, Europe, APAC, MEA and South & Central America after evaluating political, economic, social and technological factors effecting the monoamine oxidase inhibitor market in these regions.
MARKET PLAYERS
The report covers key developments in the monoamine oxidase inhibitor market as organic and inorganic growth strategies. Various companies are focusing on organic growth strategies such as product launches, product approvals and others such as patents and events. Inorganic growth strategies witnessed in the market were acquisitions, and partnership & collaborations. These activities have paved way for expansion of business and customer base of market players. The market players from monoamine oxidase inhibitor market are anticipated to have lucrative growth opportunities in the future with the rising demand for monoamine oxidase inhibitor in the global market. Below mentioned is the list of few companies engaged in the monoamine oxidase inhibitor market.
The report also includes the profiles of key players in monoamine oxidase inhibitor market along with their SWOT analysis and market strategies. In addition, the report focuses on leading industry players with information such as company profiles, products and services offered, financial information of last 3 years, key development in past five years.
- Novartis
- Pfizer, Inc.
- Validus Pharmaceuticals LLC
- Eli Lilly and Company
- GlaxoSmithKline
- Merck & Co.
- Concordia Pharms, Inc.
- Takeda Pharmaceutical Company Limited
- Mylan N.V.
- Bristol-Myers Squibb Company
The Insight Partner's dedicated research and analysis team consists of experienced professionals with advanced statistical expertise and offers various customization options in the existing study.